Do Largest Basal Tumor Diameter and the American Joint Committee on Cancer's Cancer Staging Influence Prognostication by Gene Expression Profiling in Choroidal Melanoma

Autor: Tiffany Sara Liu, Leslie M. Niziol, Miguel A. Materin, Cem Ozgonul, Zeynep Gursel Ozkurt, David C. Musch, Naziha Slimani, Hakan Demirci
Rok vydání: 2017
Předmět:
0301 basic medicine
Oncology
Adult
Male
medicine.medical_specialty
Adolescent
Kaplan-Meier Estimate
Disease-Free Survival
Metastasis
Cohort Studies
03 medical and health sciences
Basal (phylogenetics)
0302 clinical medicine
International Classification of Diseases
Risk Factors
Internal medicine
medicine
Humans
Stage (cooking)
Fluorescein Angiography
Neoplasm Metastasis
Melanoma
Survival analysis
Cancer staging
Aged
Neoplasm Staging
Probability
Retrospective Studies
Aged
80 and over
business.industry
Choroid Neoplasms
Gene Expression Profiling
Ciliary Body
Cancer
Retrospective cohort study
Middle Aged
medicine.disease
United States
Neoplasm Proteins
Ophthalmology
030104 developmental biology
030221 ophthalmology & optometry
Female
business
hormones
hormone substitutes
and hormone antagonists
Tomography
Optical Coherence
Cohort study
Zdroj: American journal of ophthalmology. 195
ISSN: 1879-1891
Popis: PURPOSE To evaluate the prognostication of choroidal melanoma (CM) by the gene expression profiling (GEP) test. DESIGN Cohort study. METHODS Retrospective review of 293 CM patients from 2 centers. RESULTS Of 293 patients, 132 (45%) were class 1A by GEP, 63 (22%) were class 1B, and 98 (33%) were class 2. Class 2 tumors had more ciliary body involvement and greater largest basal dimension (LBD), and were thicker. GEP results and increasing LBD were independently predictive of time to metastasis. Kaplan-Meier survival analysis estimated the probability of 3-year metastasis-free survival (MFS) of 0.99 in class 1A, 0.90 in class 1B, and 0.60 in class 2. The probability of 3-year MFS was 0.49 in class 2 patients with LBD ≥ 12 mm vs 1.00 in those with LBD < 12 mm, 0.89 in class 1B with LBD ≥ 12 mm vs 0.93 in those with LBD < 12 mm, and 0.99 in class 1A with LBD ≥ 12 mm vs 1.00 in those with LBD < 12 mm. In American Joint Committee on Cancer (AJCC) stage I CMs, the probability of 3-year MFS was 1.0 for class 1A and 1B, and 0.79 for class 2. In stage II CMs, the probability of 3-year MFS was 0.99 for class 1A, 0.89 for class 1B, and 0.61 for class 2. In stage III CM, the probability of 3-year MFS was 1.0 for class 1A, 0.60 for class 1B, and 0.41 for class 2. CONCLUSIONS GEP testing provided significant prognostic information for CM. Class 2 tumors with LBD ≥ 12 mm and class 2 and 1B tumors with AJCC stage III showed significantly worse prognosis.
Databáze: OpenAIRE
Externí odkaz: